NoneNo Change
BMI
Dulaglutide → BMI
Dulaglutide → BMI
Evidence profile
NoneNo ChangeWeight & Anthropometrics
Unlock full evidence details
Research Summary
Analyzed using Evidence Intelligence™
GLP-1 agonists reduce heart fat thickness in diabetes.
Key finding
Epicardial adipose tissue thickness significantly decreased in the semaglutide group (P < 0.01).
Semaglutide and dulaglutide administered weekly to adults with type 2 diabetes and obesity.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Some Concerns bias
Last updated July 5, 2026Quick read
Study at a glance
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Semaglutide, Dulaglutide, Metformin
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Primary outcome
Epicardial adipose tissue thickness
Comparator
Metformin Group
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
Semaglutide and dulaglutide administered weekly to adults with type 2 diabetes and obesity.
Clinical relevance
This study evaluated Semaglutide and dulaglutide administered weekly to adults with type 2 diabetes and obesity.
Keep in mind
Limitations were not clearly described in the extracted text.
Published in
Journal Reference
Publication details and source links for this paper.
Gianluca I, Alexandra CVF. Weekly administration of GLP-1 receptor agonists semaglutide or dulaglutide reduces epicardial adipose tissue thickness. Journal of the Endocrine Society. 2020;4(4):bvz042. doi:10.1210/jendso/bvz042
Save this study and add notes to your research library.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Dulaglutide, Metformin, Semaglutide and BMI, Epicardial adipose tissue thickness, HbA1c.
This study contributes evidence to
Primary intervention
Dulaglutide
Primary outcomes
- BMI
- Epicardial adipose tissue thickness
- HbA1c
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
8
Evidence pairs
8
Relationships
4
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
4
Related topics
8
Evidence pairs
306
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 8 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Core evidence
Study findings
The primary outcomes reported in this study.
StrongDecrease
Epicardial adipose tissue thickness
Dulaglutide → Epicardial adipose tissue thickness
Dulaglutide → Epicardial adipose tissue thickness
Evidence profile
StrongDecreaseClinical Outcomes
Unlock full evidence details
NoneNo Change
HbA1c
Dulaglutide → HbA1c
Dulaglutide → HbA1c
Evidence profile
NoneNo ChangeGlycemic Control
Unlock full evidence details
NoneNo Change
BMI
Metformin → BMI
Metformin → BMI
Evidence profile
NoneNo ChangeWeight & Anthropometrics
Unlock full evidence details
NoneNo Change
HbA1c
Metformin → HbA1c
Metformin → HbA1c
Evidence profile
NoneNo ChangeGlycemic Control
Unlock full evidence details
NoneNo Change
BMI
Semaglutide → BMI
Semaglutide → BMI
Evidence profile
NoneNo ChangeWeight & Anthropometrics
Unlock full evidence details
StrongDecrease
Epicardial adipose tissue thickness
Semaglutide → Epicardial adipose tissue thickness
Semaglutide → Epicardial adipose tissue thickness
Evidence profile
StrongDecreaseClinical Outcomes
Unlock full evidence details
NoneNo Change
HbA1c
Semaglutide → HbA1c
Semaglutide → HbA1c
Evidence profile
NoneNo ChangeGlycemic Control
Unlock full evidence details
Unlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, Metformin Therapies and HbA1c.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
11 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
11 studies
outcome_hubMeasures HbA1c as a key outcome.
Metformin Therapies Evidence Hub
All studies on Metformin Therapies
7 studies
intervention_hubContributes to Metformin Therapies evidence base.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Semaglutide and HbA1c
Intervention: SemaglutideOutcome: HbA1c
11 results
All studies on Metformin and HbA1c
Intervention: MetforminOutcome: HbA1c
7 results
All studies on Semaglutide
Intervention: Semaglutide
11 results
All studies on Metformin
Intervention: Metformin
7 results
All studies measuring HbA1c
Outcome: HbA1c
11 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists improve HbA1c?
Moderate Evidence
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 69.8 | strong positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 24 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Metformin Therapies improve HbA1c?
Emerging Evidence
Metformin Therapies may improve HbA1c.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 61.9 | moderate positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 8 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect body mass index?
Emerging Evidence
GLP-1 Receptor Agonists may improve Body Mass Index.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Emerging | EvidenceScore™ 55.2 | moderate positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 9 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Metformin Therapies affect body mass index?
Emerging Evidence
Metformin Therapies may improve Body Mass Index.
ConsensusScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Emerging | EvidenceScore™ 48.4 | moderate positive | ConsensusScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetesHigher semaglutide doses improve glucose control in type 2 diabetesNovel Semaglutide Injection Shows Non-Inferior Glycemic ControlOral semaglutide may improve cardiovascular event prevention in type 2 diabetes.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.